The views, information, or opinions expressed in the Industry News RSS feed belong solely to the author and do not necessarily represent those of IDEX Health & Science and its employees.
Article obtained from Photonics RSS Feed.
Epic Sciences Inc., a diagnostics and disease profiling company, announced it has entered into an exclusive license and collaboration agreement with the University of Southern California (USC) Michelson Center for Convergent Bioscience, and the center’s Dr. Peter Kuhn, who leads USC’s Convergent Science Institute in Cancer (CSI-Cancer). The collaboration enhances the ability to provide precision characterizations of rare circulating tumor cells (CTCs). Epic is currently developing CTCs into liquid biopsy diagnostics for characterizing cancers to better guide treatment decisions.
Epic’s platform uses precision optics paired with AI-trained machine vision algorithms to analyze fluorescent antibodies-treated blood….READ MORE